Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-0098PMID 21844014PMCID PMC3218300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

  2011influential reference
• A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma.

  2011cited by this paper
• Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

  2010cited by this paper
• PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

  2010cited by this paper
• The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

  2010cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma.

  2010cited by this paper
• AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1)

  2010cited by this paper
• A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma.

  2010cited by this paper
• Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

  2010cited by this paper
• Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis

  2009cited by this paper
• PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells.

  2009cited by this paper
• A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma

  2009cited by this paper
• Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

  2008cited by this paper
• Detecting PKC phosphorylation as part of the Wnt/calcium pathway in cutaneous melanoma.

  2008cited by this paper
• G‐protein‐coupled receptors and melanoma

  2008cited by this paper
• Down-Regulation of Mcl-1 by Small Interfering RNA Sensitizes Resistant Melanoma Cells to Fas-Mediated Apoptosis

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008influential reference
• Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation

  2008cited by this paper
• Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients.

  2007influential reference
• Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis

  2007influential reference
• Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.

  2007influential reference
• Rewired ERK-JNK signaling pathways in melanoma.

  2007cited by this paper
• Cutaneous melanoma: available therapy for metastatic disease

  2006cited by this paper
• Mortality due to Amyotrophic Lateral Sclerosis and Parkinson’s Disease among Melanoma Patients

  2006cited by this paper
• Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.

  2006cited by this paper
• Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

  2006cited by this paper
• Another dimension to calcium signaling: a look at extracellular calcium

  2005cited by this paper
• Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation*

  2005cited by this paper
• The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

  2005cited by this paper
• The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

  2005cited by this paper
• Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis

  2005cited by this paper
• Treatment of advanced melanoma with temozolomide: II.

  2004cited by this paper
• Treatment of advanced melanoma with temozolomide: I.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004influential reference
• Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia

  2003influential reference
• Group I metabotropic glutamate receptor‐mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons

  2003cited by this paper
• Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Glutamate antagonists limit tumor growth.

  2002cited by this paper
• Glutamate antagonists limit tumor growth

  2001cited by this paper
• Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.

  2001cited by this paper
• Riluzole, a glutamate release inhibitor, and motor behavior

  1998cited by this paper
• The pharmacology and mechanism of action of riluzole

  1996cited by this paper
• The metabotropic glutamate receptors: structure and functions.

  1995cited by this paper
• G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity.

  1991cited by this paper
• Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes.

  1991cited by this paper
• Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation.

  1989cited by this paper

• DLEU1 as a key regulator in glioblastoma: A review of ferroptosis resistance, tumor microenvironment interactions, and emerging RNA-based therapeutic strategies.

  2025cites this paper
• miR-199a-5p/GPR89A axis modulates sorafenib resistance in hepatocellular carcinoma through glutamate metabolic reprogramming

  2025cites this paper
• In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM

  2024cites this paper
• Riluzole Enhancing anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer.

  2024cites this paper
• A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850

  2023cites this paper
• Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs

  2023cites this paper
• Riluzole regulates pancreatic cancer cell metabolism by suppressing the Wnt-β-catenin pathway

  2022cites this paper
• lncRNA-AC130710/miR-129-5p/mGluR1 axis promote migration and invasion by activating PKCα-MAPK signal pathway in melanoma

  2022cites this paper
• Concomitant Antihyperalgesic and Antitumor Effects of Gabapentin in a Murine Cancer Pain Model

  2021cites this paper
• Blood glutamate scavengers increase pro-apoptotic signaling and reduce metastatic melanoma growth in-vivo

  2021cites this paper
• Riluzole: A neuroprotective drug with potential as a novel anti-cancer agent (Review)

  2021cites this paper
• Neuroendocrine Factors in Melanoma Pathogenesis

  2021cites this paper
• Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway

  2020cites this paper
• Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.

  2020cites this paper
• New drugs are not enough-drug repositioning in oncology: An update

  2020cites this paper
• Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

  2020cites this paper
• Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent

  2020cites this paper
• 2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.

  2020cites this paper
• Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.

  2019cites this paper
• Amyotrophic Lateral Sclerosis, a Possible Sequela of Chronic Myeloid Leukemia

  2019cites this paper
• Targeting Glutamate Metabolism in Melanoma

  2019cites this paper
• Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo

  2018cites this paper
• A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

  2018cites this paper
• Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells.

  2017cites this paper
• Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma

  2017cites this paper
• Metabotropic glutamate receptors in cancer

  2017cites this paper
• Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells

  2017cites this paper
• Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.

  2017cites this paper
• The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis

  2016cites this paper
• Glutamate Receptor Agonists and Glutamate Transporter Antagonists Regulate Differentiation of Osteoblast Lineage Cells

  2016cites this paper
• Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1

  2016cites this paper
• The current management of brain metastasis in melanoma: a focus on riluzole

  2015influential citation
• Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain

  2015cites this paper
• Riluzole is a radio‐sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells

  2015cites this paper
• Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

  2015cites this paper
• Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?

  2015cites this paper
• Synthesis and evaluation of 4-halogeno-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide for imaging of metabotropic glutamate 1 receptor in melanoma.

  2015cites this paper
• Riluzole activates TRPC5 channels independently of PLC activity

  2014cites this paper
• Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin‐like growth factor 1 receptor

  2014cites this paper
• Metabotropic Glutamate Receptor 1 acts as a Dependence Receptor Creating a Requirement for Glutamate to Sustain the Viability and Growth of Human Melanomas

  2014cites this paper
• 1H NMR metabolomics study of metastatic melanoma in C57BL/6J mouse spleen

  2014cites this paper
• The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.

  2014cites this paper
• Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18F‐FITM

  2014cites this paper
• Metabotropic glutamate receptor 1 in human malignancies

  2013cites this paper
• Treatment strategies for melanoma: pharmacological and toxicological action mechanisms of combined therapies

  2013cites this paper
• Genetics of melanoma

  2013influential citation
• GRM1, A POTENTIAL TARGET FOR HUMAN MELANOMA

  2013cites this paper
• U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo

  2013cites this paper
• The influence of glutamate receptors on proliferation and metabolic cell activity of neuroendocrine tumors.

  2013cites this paper
• Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes

  2013cites this paper
• Comprehensive Genomic Characterization of Cutaneous Malignant Melanoma Cell Lines Derived from Metastatic Lesions by Whole-Exome Sequencing and SNP Array Profiling

  2013cites this paper
• Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications

  2013cites this paper
• Cancer Genes and Genomics Functional Effects of GRM 1 Suppression in Human Melanoma Cells

  2012cites this paper
• Functional Effects of GRM1 Suppression in Human Melanoma Cells

  2012cites this paper
• Glutamatergic signaling in cellular transformation

  2012cites this paper
• Analysis of gene expression alterations in premalignant progression from normal mammary epithelium to ductal carcinoma in situ by multiple orthogonal tools

  2012cites this paper
• Highly pigmented Tg(Grm1) mouse melanoma develops non‐pigmented melanoma cells in distant metastases

  2012cites this paper
• Delving into somatic variation in sporadic melanoma

  2012influential citation
• The association between cancer and amyotrophic lateral sclerosis

  2012cites this paper
• Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma

  2012cites this paper
• Metabotropic Glutamate Receptor 1 (Grm1) Is An Oncogene In Epithelial Cells

  2012cites this paper
• Blocking glutamate‐mediated signalling inhibits human melanoma growth and migration

  2012cites this paper
• Naturally Occurring Variation in Trophoblast Invasion as a Source of Novel (Epigenetic) Biomarkers

  2012cites this paper
• Targeting Cancer Metabolism

  2012cites this paper
• Sorafenib in melanoma

  2012cites this paper
• Glutamate receptors: emerging players in melanomagenesis

  2011cites this paper
• Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development

  2010cites this paper